SK117599A3 - Dna sequence, a vector containing it, a host cell, isoform of g1 protein, method for producing isoform of g1 protein, pharmaceutical composition containing it and its use - Google Patents
Dna sequence, a vector containing it, a host cell, isoform of g1 protein, method for producing isoform of g1 protein, pharmaceutical composition containing it and its use Download PDFInfo
- Publication number
- SK117599A3 SK117599A3 SK1175-99A SK117599A SK117599A3 SK 117599 A3 SK117599 A3 SK 117599A3 SK 117599 A SK117599 A SK 117599A SK 117599 A3 SK117599 A3 SK 117599A3
- Authority
- SK
- Slovakia
- Prior art keywords
- protein
- mort
- cells
- proteins
- fas
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 484
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 473
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 102000001708 Protein Isoforms Human genes 0.000 title claims description 192
- 108010029485 Protein Isoforms Proteins 0.000 title claims description 192
- 239000013598 vector Substances 0.000 title claims description 98
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims description 344
- 230000000694 effects Effects 0.000 claims description 170
- 230000027455 binding Effects 0.000 claims description 164
- 238000009739 binding Methods 0.000 claims description 162
- 238000000034 method Methods 0.000 claims description 150
- 239000012634 fragment Substances 0.000 claims description 115
- 239000003446 ligand Substances 0.000 claims description 95
- 102000014914 Carrier Proteins Human genes 0.000 claims description 85
- 108091008324 binding proteins Proteins 0.000 claims description 85
- 239000002299 complementary DNA Substances 0.000 claims description 76
- 102000005962 receptors Human genes 0.000 claims description 75
- 108020003175 receptors Proteins 0.000 claims description 75
- 230000003834 intracellular effect Effects 0.000 claims description 74
- 230000030833 cell death Effects 0.000 claims description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 71
- 230000001404 mediated effect Effects 0.000 claims description 63
- 230000014509 gene expression Effects 0.000 claims description 58
- 230000001472 cytotoxic effect Effects 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 43
- 231100000433 cytotoxic Toxicity 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 37
- 238000010396 two-hybrid screening Methods 0.000 claims description 36
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 29
- 230000001413 cellular effect Effects 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 238000012216 screening Methods 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 23
- 102000010579 Fas-Associated Death Domain Protein Human genes 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 20
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 18
- 102000004091 Caspase-8 Human genes 0.000 claims description 16
- 108090000538 Caspase-8 Proteins 0.000 claims description 16
- 108090000994 Catalytic RNA Proteins 0.000 claims description 16
- 102000053642 Catalytic RNA Human genes 0.000 claims description 16
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 claims description 16
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 claims description 16
- 108091092562 ribozyme Proteins 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 12
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 12
- 108091008604 NGF receptors Proteins 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 10
- 108091026890 Coding region Proteins 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 239000000411 inducer Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000001086 yeast two-hybrid system Methods 0.000 claims description 9
- 102000018697 Membrane Proteins Human genes 0.000 claims description 8
- 108010052285 Membrane Proteins Proteins 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000001042 affinity chromatography Methods 0.000 claims description 7
- 230000002900 effect on cell Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000003782 apoptosis assay Methods 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 230000005522 programmed cell death Effects 0.000 claims description 4
- 239000012504 chromatography matrix Substances 0.000 claims description 2
- 230000004481 post-translational protein modification Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 101710154541 Modulator protein Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 399
- 108010052621 fas Receptor Proteins 0.000 description 202
- 102000018823 fas Receptor Human genes 0.000 description 200
- 239000004365 Protease Substances 0.000 description 92
- 102000035195 Peptidases Human genes 0.000 description 91
- 108091005804 Peptidases Proteins 0.000 description 91
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 87
- 108020004635 Complementary DNA Proteins 0.000 description 80
- 101150055276 ced-3 gene Proteins 0.000 description 80
- 102100040247 Tumor necrosis factor Human genes 0.000 description 73
- 238000010804 cDNA synthesis Methods 0.000 description 73
- 241000282414 Homo sapiens Species 0.000 description 56
- 235000019419 proteases Nutrition 0.000 description 46
- 102000010170 Death domains Human genes 0.000 description 38
- 230000003013 cytotoxicity Effects 0.000 description 38
- 231100000135 cytotoxicity Toxicity 0.000 description 38
- 108050001718 Death domains Proteins 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 36
- 230000006870 function Effects 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 33
- 238000003776 cleavage reaction Methods 0.000 description 33
- 230000004913 activation Effects 0.000 description 31
- 230000002797 proteolythic effect Effects 0.000 description 30
- 230000003993 interaction Effects 0.000 description 29
- 230000007017 scission Effects 0.000 description 29
- 238000003556 assay Methods 0.000 description 27
- 230000011664 signaling Effects 0.000 description 27
- 239000000758 substrate Substances 0.000 description 27
- 102100039556 Galectin-4 Human genes 0.000 description 24
- 102100029855 Caspase-3 Human genes 0.000 description 23
- 230000004568 DNA-binding Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 101150028668 APO1 gene Proteins 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108090000426 Caspase-1 Proteins 0.000 description 20
- 108010005774 beta-Galactosidase Proteins 0.000 description 20
- 210000004899 c-terminal region Anatomy 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 102100026189 Beta-galactosidase Human genes 0.000 description 19
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 19
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 19
- 230000005889 cellular cytotoxicity Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 18
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 18
- 239000013615 primer Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 230000004068 intracellular signaling Effects 0.000 description 17
- 231100000518 lethal Toxicity 0.000 description 17
- 230000001665 lethal effect Effects 0.000 description 17
- 230000007246 mechanism Effects 0.000 description 17
- 108020003519 protein disulfide isomerase Proteins 0.000 description 17
- 238000010367 cloning Methods 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 101000758020 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized aminotransferase BpOF4_10225 Proteins 0.000 description 15
- 101000744710 Clostridium pasteurianum Uncharacterized glutaredoxin-like 8.6 kDa protein in rubredoxin operon Proteins 0.000 description 15
- 102000036292 Death effector domains Human genes 0.000 description 15
- 108091010866 Death effector domains Proteins 0.000 description 15
- 101000653283 Enterobacteria phage T4 Uncharacterized 11.5 kDa protein in Gp31-cd intergenic region Proteins 0.000 description 15
- 101000618324 Enterobacteria phage T4 Uncharacterized 7.9 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 description 15
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 15
- 101000961876 Pyrococcus woesei Uncharacterized protein in gap 3'region Proteins 0.000 description 15
- 101001056915 Saccharopolyspora erythraea 6-deoxyerythronolide-B synthase EryA2, modules 3 and 4 Proteins 0.000 description 15
- 101000819248 Staphylococcus aureus Uncharacterized protein in ileS 5'region Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 101150066555 lacZ gene Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 101150064015 FAS gene Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000004098 Tetracycline Substances 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 230000002255 enzymatic effect Effects 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 239000007850 fluorescent dye Substances 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 229930101283 tetracycline Natural products 0.000 description 13
- 229960002180 tetracycline Drugs 0.000 description 13
- 235000019364 tetracycline Nutrition 0.000 description 13
- 150000003522 tetracyclines Chemical class 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 12
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 11
- 101710100501 CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 11
- 230000000445 cytocidal effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 10
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 10
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 10
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 10
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 10
- 102000011727 Caspases Human genes 0.000 description 9
- 108010076667 Caspases Proteins 0.000 description 9
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 9
- 108010001515 Galectin 4 Proteins 0.000 description 9
- 108010070675 Glutathione transferase Proteins 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 9
- 230000002498 deadly effect Effects 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 108010047294 Lamins Proteins 0.000 description 8
- 102000006835 Lamins Human genes 0.000 description 8
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 8
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 8
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 210000005053 lamin Anatomy 0.000 description 8
- -1 on vasculature Chemical compound 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102100035904 Caspase-1 Human genes 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012340 reverse transcriptase PCR Methods 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 6
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000004897 n-terminal region Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000003348 filter assay Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000031146 intracellular signal transduction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000003158 yeast two-hybrid assay Methods 0.000 description 4
- ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 3
- 108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 3
- 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100026549 Caspase-10 Human genes 0.000 description 3
- 102000003910 Cyclin D Human genes 0.000 description 3
- 108090000259 Cyclin D Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101001057956 Homo sapiens 55 kDa erythrocyte membrane protein Proteins 0.000 description 3
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 3
- 101001065272 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 3
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 3
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101150055709 SNF1 gene Proteins 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 108010053098 biotin receptor Proteins 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006721 cell death pathway Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108020005243 folate receptor Proteins 0.000 description 3
- 102000006815 folate receptor Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 102000057036 human EFEMP1 Human genes 0.000 description 3
- 102000043323 human PSIP1 Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000006662 intracellular pathway Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001466 metabolic labeling Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 238000003160 two-hybrid assay Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YGLOALWHJIANIH-UHFFFAOYSA-N 3-[2-[[2-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-4-[(4-methyl-2-oxochromen-7-yl)amino]-4-oxobutanoic acid Chemical compound C=1C=C2C(C)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 YGLOALWHJIANIH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101000835846 Arabidopsis thaliana Sucrose nonfermenting 4-like protein Proteins 0.000 description 2
- 108700032588 Baculovirus p35 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101150009006 HIS3 gene Proteins 0.000 description 2
- 101000734668 Homo sapiens Astrocytic phosphoprotein PEA-15 Proteins 0.000 description 2
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 2
- 101000799554 Homo sapiens Protein AATF Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 101100495513 Mus musculus Cflar gene Proteins 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100034180 Protein AATF Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100024483 Sororin Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- 108010001244 Tli polymerase Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 108091006116 chimeric peptides Proteins 0.000 description 2
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000013198 immunometric assay Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010064752 interleukin 1beta-converting enzyme 2 Proteins 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000010397 one-hybrid screening Methods 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KTPDNYVWXJTUKG-UHFFFAOYSA-O 1-methyl-2-[2-(2-phenyl-1h-indol-3-yl)ethenyl]quinolin-1-ium Chemical compound C1=CC2=CC=CC=C2[N+](C)=C1\C=C\C(C1=CC=CC=C1N1)=C1C1=CC=CC=C1 KTPDNYVWXJTUKG-UHFFFAOYSA-O 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710093560 34 kDa protein Proteins 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 102100034691 Astrocytic phosphoprotein PEA-15 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100220233 Caenorhabditis elegans ced-3 gene Proteins 0.000 description 1
- 101710140962 Capsid scaffolding protein Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102100028183 Cytohesin-interacting protein Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101100273284 Homo sapiens CASP4 gene Proteins 0.000 description 1
- 101000859758 Homo sapiens Cartilage-associated protein Proteins 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000964421 Homo sapiens Zinc finger and BTB domain-containing protein 12 Proteins 0.000 description 1
- RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000824268 Kuma Species 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018721 Macroglobulins Human genes 0.000 description 1
- 108010091934 Macroglobulins Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 101000761459 Mesocricetus auratus Calcium-dependent serine proteinase Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 101100059157 Mus musculus Casp2 gene Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 102100029000 Prolactin receptor Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108700040800 TNF Receptor-Associated Death Domain Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 102100040328 Zinc finger and BTB domain-containing protein 12 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- HKPHPIREJKHECO-UHFFFAOYSA-N butachlor Chemical compound CCCCOCN(C(=O)CCl)C1=C(CC)C=CC=C1CC HKPHPIREJKHECO-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000048443 human FADD Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000730 protein immunoprecipitation Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12036797A IL120367A0 (en) | 1997-03-03 | 1997-03-03 | Modulators of the function of FAS receptors and other proteins |
| IL12075997A IL120759A0 (en) | 1997-03-03 | 1997-05-01 | Modulators of the function of fas receptors and other proteins |
| PCT/IL1998/000098 WO1998039435A1 (en) | 1997-03-03 | 1998-02-26 | Cash (caspase homologue) with death effector domain, modulators of the function of fas receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK117599A3 true SK117599A3 (en) | 2000-05-16 |
Family
ID=26323378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1175-99A SK117599A3 (en) | 1997-03-03 | 1998-02-26 | Dna sequence, a vector containing it, a host cell, isoform of g1 protein, method for producing isoform of g1 protein, pharmaceutical composition containing it and its use |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7419804B2 (ko) |
| EP (1) | EP0977842A1 (ko) |
| JP (1) | JP2002500508A (ko) |
| KR (1) | KR100544776B1 (ko) |
| CN (1) | CN1148446C (ko) |
| AU (1) | AU740223B2 (ko) |
| BG (1) | BG64799B1 (ko) |
| BR (1) | BR9808173A (ko) |
| CA (1) | CA2281484A1 (ko) |
| EA (1) | EA003269B1 (ko) |
| EE (1) | EE9900384A (ko) |
| HK (1) | HK1024508A1 (ko) |
| HU (1) | HUP0000913A3 (ko) |
| IL (3) | IL120759A0 (ko) |
| NO (1) | NO994250L (ko) |
| NZ (1) | NZ337143A (ko) |
| PL (1) | PL193394B1 (ko) |
| SK (1) | SK117599A3 (ko) |
| WO (1) | WO1998039435A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19713393C2 (de) * | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| DE19713434C1 (de) * | 1997-04-01 | 1998-09-24 | Deutsches Krebsforsch | Protein zur Inhibierung von Apoptose |
| JP2002520025A (ja) * | 1998-07-08 | 2002-07-09 | メルク フロスト カナダ アンド カンパニー | 哺乳動物ｄｅｄ−カスパーゼ相同体ユサルピン |
| US7052834B1 (en) | 1998-12-31 | 2006-05-30 | St. Jude Children's Research Hospital | Tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein |
| WO2000039347A1 (en) * | 1998-12-31 | 2000-07-06 | St. Jude Children's Research Hospital | A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein |
| US20020174450A1 (en) * | 2000-12-11 | 2002-11-21 | Allen Keith D. | Transgenic mice containing cash gene disruptions |
| CN110988354A (zh) * | 2019-11-15 | 2020-04-10 | 同济大学 | 一种分泌蛋白Caspase1在早期心梗诊断试剂中的应用 |
| CN116426678B (zh) * | 2023-03-27 | 2024-03-22 | 中国热带农业科学院三亚研究院 | 与番木瓜果肉果糖含量相关的snp分子标记及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114615A0 (en) | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
| EP0841399A3 (en) * | 1996-11-12 | 1998-07-08 | Smithkline Beecham Corporation | Mammalian fin-1 nucleic acid (a caspase) and protein sequences and uses therefor |
| JP2001511011A (ja) | 1997-01-21 | 2001-08-07 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | 腫瘍壊死因子レセプター−１誘導性アポトーシスおよびｃｄ−９５誘導性アポトーシスの新規なインヒビターである、ｉ−ｆｌｉｃｅ |
| US6242569B1 (en) | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
| DE19713393C2 (de) * | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| US6207458B1 (en) * | 1998-05-07 | 2001-03-27 | University Of Washigton/Stowers Insitute For Medical Research | Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same |
-
1997
- 1997-05-01 IL IL12075997A patent/IL120759A0/xx unknown
-
1998
- 1998-02-26 JP JP53833198A patent/JP2002500508A/ja not_active Ceased
- 1998-02-26 HU HU0000913A patent/HUP0000913A3/hu unknown
- 1998-02-26 CA CA002281484A patent/CA2281484A1/en not_active Abandoned
- 1998-02-26 SK SK1175-99A patent/SK117599A3/sk unknown
- 1998-02-26 KR KR1019997007790A patent/KR100544776B1/ko not_active IP Right Cessation
- 1998-02-26 CN CNB988030748A patent/CN1148446C/zh not_active Expired - Fee Related
- 1998-02-26 EP EP98905598A patent/EP0977842A1/en not_active Withdrawn
- 1998-02-26 PL PL98335448A patent/PL193394B1/pl unknown
- 1998-02-26 AU AU61126/98A patent/AU740223B2/en not_active Ceased
- 1998-02-26 NZ NZ337143A patent/NZ337143A/en unknown
- 1998-02-26 WO PCT/IL1998/000098 patent/WO1998039435A1/en active IP Right Grant
- 1998-02-26 BR BR9808173-0A patent/BR9808173A/pt not_active Application Discontinuation
- 1998-02-26 EA EA199900794A patent/EA003269B1/ru not_active IP Right Cessation
- 1998-02-26 IL IL13124798A patent/IL131247A0/xx active IP Right Grant
- 1998-02-26 EE EEP199900384A patent/EE9900384A/xx unknown
-
1999
- 1999-08-04 IL IL131247A patent/IL131247A/en not_active IP Right Cessation
- 1999-08-26 BG BG103693A patent/BG64799B1/bg unknown
- 1999-09-02 NO NO994250A patent/NO994250L/no not_active Application Discontinuation
-
2000
- 2000-06-23 HK HK00103826A patent/HK1024508A1/xx not_active IP Right Cessation
-
2006
- 2006-06-08 US US11/448,842 patent/US7419804B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA199900794A1 (ru) | 2000-04-24 |
| CA2281484A1 (en) | 1998-09-11 |
| BG64799B1 (bg) | 2006-04-28 |
| NO994250D0 (no) | 1999-09-02 |
| US20060216788A1 (en) | 2006-09-28 |
| HK1024508A1 (en) | 2000-10-13 |
| IL120759A0 (en) | 1997-09-30 |
| NZ337143A (en) | 2001-12-21 |
| HUP0000913A3 (en) | 2001-11-28 |
| EP0977842A1 (en) | 2000-02-09 |
| WO1998039435A1 (en) | 1998-09-11 |
| AU740223B2 (en) | 2001-11-01 |
| NO994250L (no) | 1999-11-02 |
| HUP0000913A2 (hu) | 2000-06-28 |
| EE9900384A (et) | 2000-04-17 |
| CN1148446C (zh) | 2004-05-05 |
| US7419804B2 (en) | 2008-09-02 |
| BR9808173A (pt) | 2000-05-16 |
| CN1249780A (zh) | 2000-04-05 |
| JP2002500508A (ja) | 2002-01-08 |
| IL131247A0 (en) | 2001-01-28 |
| EA003269B1 (ru) | 2003-02-27 |
| PL193394B1 (pl) | 2007-02-28 |
| KR20000075721A (ko) | 2000-12-26 |
| BG103693A (en) | 2000-05-31 |
| KR100544776B1 (ko) | 2006-01-23 |
| IL131247A (en) | 2007-08-19 |
| AU6112698A (en) | 1998-09-22 |
| PL335448A1 (en) | 2000-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7799901B2 (en) | Modulators of the function of FAS receptors and other proteins | |
| US20080159986A1 (en) | Modulators of the functions of receptors of the tnf/ngf receptor family and other proteins | |
| US7419804B2 (en) | CASH (Caspase Homologue) with death effector domain, modulators of the function of FAS | |
| JP4351389B2 (ja) | Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質 | |
| RU2235779C2 (ru) | Последовательность днк, кодирующая полипептид, который связывается с mort-1 (варианты), полипептид (варианты) и способ его получения, вектор, способ модулирования действия лиганда fas-r или tnf на клетки (варианты), способ обработки клеток, способ выделения и идентификации белков, способ модулирования индуцируемого mort-1 действия или индуцируемого mort-1 связывающим белком действия на клетки | |
| US7407771B2 (en) | Cash (caspase homologue) with death effector domain, modulators of the function of FAS receptors | |
| US6808891B2 (en) | Modulators of the function of FAS/APO1 receptors | |
| RU2241747C2 (ru) | Молекула днк, кодирующая полипептид, способный связываться с внутриклеточным доменом рецептора лиганда fas(fas-ic), полипептид, способ его получения, вектор, способ модуляции действия лиганда fas-r на клетки (варианты), фармацевтическая композиция (варианты), спрособ выделения и идентификации белка | |
| JP2009148285A (ja) | Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質 | |
| CZ314699A3 (cs) | Sekvence DNA, vektor a protein | |
| MXPA99008102A (en) | Cash (caspase homologue) with death effector domain, modulators of the function of fas receptors | |
| MXPA99008574A (en) | Modulators of the function of receptors of the tnf/ngf receptor family |